Our top pick for
Long-term investors
Proteostasis Therapeutics Inc is a biotechnology business based in the US. Proteostasis Therapeutics shares (PTI) are listed on the NASDAQ and all prices are listed in US Dollars. Proteostasis Therapeutics employs 44 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Proteostasis Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PTI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Proteostasis Therapeutics stock price (NASDAQ: PTI)
Use our graph to track the performance of PTI stocks over time.Proteostasis Therapeutics shares at a glance
Information last updated 2021-02-21.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $2.64 |
| 200-day moving average | $1.40 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.50 |
Buy Proteostasis Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Proteostasis Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Proteostasis Therapeutics financials
| Gross profit TTM | $5 million |
|---|---|
| Return on assets TTM | -31.16% |
| Return on equity TTM | -72.38% |
| Profit margin | 0% |
| Book value | $0.71 |
| Market capitalisation | $2.9 million |
TTM: trailing 12 months
Proteostasis Therapeutics share dividends
We're not expecting Proteostasis Therapeutics to pay a dividend over the next 12 months.
Have Proteostasis Therapeutics's shares ever split?
Proteostasis Therapeutics's shares were split on a 1:20 basis on 22 December 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Proteostasis Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Proteostasis Therapeutics shares which in turn could have impacted Proteostasis Therapeutics's share price.
Proteostasis Therapeutics share price volatility
Over the last 12 months, Proteostasis Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Proteostasis Therapeutics's is 1.1167. This would suggest that Proteostasis Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Proteostasis Therapeutics overview
Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc.
Proteostasis Therapeutics in the news
Frequently asked questions
What percentage of Proteostasis Therapeutics is owned by insiders or institutions?Currently 15.299% of Proteostasis Therapeutics shares are held by insiders and 22.571% by institutions. How many people work for Proteostasis Therapeutics?
Latest data suggests 44 work at Proteostasis Therapeutics. When does the fiscal year end for Proteostasis Therapeutics?
Proteostasis Therapeutics's fiscal year ends in December. Where is Proteostasis Therapeutics based?
Proteostasis Therapeutics's address is: 80 Guest Street, Boston, MA, United States, 02135 What is Proteostasis Therapeutics's ISIN number?
Proteostasis Therapeutics's international securities identification number is: US74373B1098 What is Proteostasis Therapeutics's CUSIP number?
Proteostasis Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74373B109
More guides on Finder
-
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
-
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
-
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
-
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
-
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
-
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
-
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
-
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Ask an Expert